GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Deucravacitinib - SOTYKTU tablets

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

An RX mirror and its underlying label are not independent clinical confirmations.

Check source scope before reading a dose

SOTYKTU: selected RX renal passage

Product / population
Adult oral SOTYKTU for its labeled indications; renal instruction does not waive other eligibility and safety requirements.
Renal method
Qualitative renal categories, explicitly including ESRD on dialysis
Source revision
Revision date not established in reviewed mirror passage.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

SOTYKTU: source applicability and renal evidence limits

The RX pharmacokinetic paragraph contains a malformed lower-bound value. Only the intact explicit renal-use instruction is summarized; the numerical anomaly remains disclosed.

What to reconcile: Use the explicit renal paragraph; do not use the malformed RX PK range.

Selected-source comparison; independent clinician adjudication pending.

Open this note and its source references
Rxlist

SOTYKTU: selected RX renal passage

Open original reference

GlobalRPh RX List / label mirror · Adult oral SOTYKTU for its labeled indications; renal instruction does not waive other eligibility and safety requirements.

Renal method: Qualitative renal categories, explicitly including ESRD on dialysis
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding

No CRRT settings or modality-specific schedule supplied in the selected section.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 8.6

The explicit renal-use paragraph supports no adjustment, including ESRD on dialysis. A malformed numerical range in the mirror PK paragraph was excluded; it was not corrected by guessing.

RDM72-deucravacitinib-sotyktu-rx-1 · Source locator: Section 8.6

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/sotyktu-drug/
Retrieved
2026-11-07
Renal-function method
Qualitative renal categories, explicitly including ESRD on dialysis
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
0da22edcdca2b7d50c102ca6bc674d1608233388cbb5239c875cc69e177113b6

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=deucravacitinib-sotyktu&s1=RDM72-deucravacitinib-sotyktu-rx&h1=8ee1da044df1e1ee3142ac4bda7501cb5fa08937b5cc4aeee08956c9c4a8f9b4

Top